Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Apr 26, 2021

Keywords

ClinConnect Summary

Over the past two decades in Senegal, the scale-up of malaria control measures \[e.g., access to prompt testing and case management, LLINs, and SMC\] has led to a 78% reduction in malaria incidence. However, gains have not been uniform, with lower transmission areas in the north implementing pre-elimination activities and higher transmission areas in the south implementing control interventions (including SMC). The purpose of this study is determine whether MDA will be able to rapidly reduce malaria incidence in areas of moderate-to-low malaria transmission of southern Senegal (where contro...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥3 months
• • Willingness to comply with trial procedures and written informed consent to be obtained at the beginning of the study
• Exclusion Criteria:
• • Severe illness or self-reported chronic illness (e.g., HIV, tuberculosis, heart/liver/kidney disease, and severe malnutrition)
• • Known hypersensitivity to study drug
• Additional exclusion criteria for DHA-PPQ:
• • First trimester pregnancy assessed by history and/or urine pregnancy testing
• • Concurrent artemisinin-based combination therapy (ACT) use
• • Taking drugs that influence cardiac function or prolong QTc interval
• Additional exclusion criteria for PQ:
• • Pregnancy (any trimester) or currently breastfeeding an infant \<6 months of age assessed by history and/or urine pregnancy testing
• • \<2 years of age